Ex-vivo Delivery of Rituximab to Prevent Post-transplant Lymphoproliferative Disease in Epstein-Barr Virus Mismatch Lung Transplant Recipients: A Pilot Trial
Latest Information Update: 05 Jul 2023
Price :
$35 *
At a glance
- Drugs Rituximab (Primary)
- Indications Epstein-Barr virus infections; Post-transplant lymphoproliferative disorder
- Focus Therapeutic Use
- 29 Jul 2022 Planned End Date changed from 7 Jul 2021 to 7 Feb 2023.
- 29 Jul 2022 Planned primary completion date changed from 7 Jul 2021 to 7 Dec 2022.
- 14 Aug 2020 New trial record